Blood: The new alternative to the ditric ludes, acute grafts for host disease!

Acute Transplant Anti-Host Disease (GVHD) is a life-threatening complication of allo-HCTThe current GVHD treatment is primarily aimmunesystem that targets the donor, and a recent study in the journal Blood, Norona and others have explored a method designed to protect and regenerate Paneth cells (PCs) and intestinalstem cells(ISCs)researchers observed that acute GVHD reduced intestinal GLP-2 levels in mice and GVHD patientsIn several mouse models, treatments using GLP-2 agonists, teduglutide, reduce the occurrence of acute GVHD and steroid refractive GVHD with new hairstyles, and do not affect the effects of the graft anti-leukemia (GVL)in the mechanism, GLP-2 substitution promotes the regeneration of PC and ISC, thus enhancing the production of antimicrobial peptides and causing changes in the microbiomeGLP-2 expands intestinal organs and reduces the expression of apoptosis-related genesin patients receiving allo-HCT, the low number of L cells in intestinal tissue biopsies and high serum GLP-2 levels were associated with high non-recurrence mortality, this study suggests that L cells are a target for GVHD, and that GLP-2-based acute GVHD therapy can restore intestinal stability by increasing ISC and PC without affecting The Effect of GVLThe dyded ludtide is expected to become a new joint partner of GVHD immunosuppressive therapy and can be validated in clinical trialscover picture: The ditrilutide therapy reduced the loss of Paneth cells in GVHD mice